NT5E and Miyoshi myopathy: found that targeted CD73 therapy, alone or in combination with an immune stimulant TLR-7 agonist, can enhance the activity of MM-specific CD8+ cytotoxic T cells, which is a promising new strategy to restore patients’ anti-MM immunity (23, 82).